Yeah, you just waste your time posting about how useless other peoples' posts are. I get it now.. you're just another troll... into ignoreworld you go.
Go tell that to the OP too, cause I read nothing in what he said that shed any real insights either. Speaking of which, how about impressing us with your great analytical skills huh?
Well it got close but never dipped below 5 and so unfortunately I did not get any bargain-bin priced shares of SAN. Now less than a month later it's back trading around 6 where I added back in early Sept. Oh well.
Looks like Dell is pushing ahead with a takeover of EMC, and wants to hold onto VMW too. Seems like they want to close a deal before HPQ splits up since I'd think HP Enterprise would want to do an EMC deal too.
@In addition to the cash offer of $27.25 a share, Dell would give investors what’s known as a tracking stock in VMware, the cloud software company that’s 80 percent owned by EMC. That stock would “track” the value of the remaining 20 percent of VMware that openly trades. Together that would bring the per-share value above $30, according to sources. Another element to the deal involves VMware, which is “considered the crown jewel of the federation and Michael wants to hold on to it,” as one source put it, suggesting Dell would retain a majority stake in VMware even after redistributing some of its shares. CNBC’s Faber reported Friday that the deal may include issuing tracking stock in VMware.
Could be a bad or good time to bail out. As they say though... no guts, no glory. Adoption of oled technology is set to go mainstream in 2016 provided LG successfully ramps TV's, and shareholders will finally learn if this company is a money-making machine or a dead end with mediocre management that is unable to fully leverage the IP to grow profits.
@Credit Suisse believes that a potential Dell Inc. (NASDAQ: DELL)/EMC Corporation (NYSE: EMC) merger makes more sense if VMware, Inc. (NYSE: VMW) is first spun out. A spinout would open up the door for VMware to be more aggressively competitive with EMC and other storage rivals. Credit Suisse also views an independent VMware as an attractive buyout target for larger names. Buyout Target In addition to the freedom to take a more aggressive competitive approach, Winslow believes that an independent VMware would immediately become a buyout target for larger tech companies. He mentioned Oracle Corporation (NYSE: ORCL), International Business Machines Corp. (NYSE: IBM), Hewlett-Packard Company (NYSE: HPQ) and Cisco Systems, Inc. (NASDAQ: CSCO) as potential buyers. Credit Suisse currently has an Outperform rating on VMware and a $130 target for the stock
Any further pools of blood will be spilled by the EPA, which was unable to detect the issue for years. How many other violations are going on that they are unaware of? This is at least as a big a hit to their credibility as to the car maker.
Bloodbath? VW stock price has been cut in half. That WAS the bloodbath.
Take a look at LME aluminum inventory levels.(nice base metals charts at kitcometals). Al stock levels have been in a freefall since summer of 2014. AA predicts a supply deficit of the metal in 2016.
As I understand it, VW can alter engine control programs to meet emission requirements. The trade-off is reduced engine performance. So I'm not sure what you want the EPA to provide guidance on. Ultimately, VW will have to make the necessary software (and perhaps some minor hardware) changes, and reduce the price of the affected vehicles to entice customers to purchase them. They will also have to pay fines and settle class action suits. In the end VW will survive.
Deal is cleared to proceed and is set to close Nov 2.
@TORONTO , Oct. 7, 2015 /CNW/ - Royal Bank of Canada (RY on TSX and NYSE) and City National Corporation (CYN on NYSE) announced that they received formal regulatory approval today from the Board of Governors of the Federal Reserve System to complete Royal Bank of Canada's acquisition of City National pursuant to their merger agreement previously announced on January 22, 2015 . This follows approval from the Office of the Superintendent of Financial Institutions. The merger is expected to close on November 2, 2015 , subject to the satisfaction of customary closing conditions.
The DJ asset was a significant producer of oil at 10k+ bbls/day and touted as a growth play by ECA so it must have been a tough decision to let it go while continuing to hold onto a non-core dog asset like Panuke. I understand why they did the sale, but it seems they have sold DJ just as oil prices are showing signs of recovering.... another case of horrible timing?
Me too. Nothing about the way this stock trades makes any sense to me either. I guess the fear is that if Dell does manage to acquire EMC, they will control VMW and that is apparently a bad thing for VMW. I always though that VMW would be a decent fit for a company like HPQ or IBM or Dell vs. a pure storage player like EMC.
The adverse decision to review the Lialda patent, announced yesterday, did not appear to have any significant impact on SHPG stock price today, so I decided to add some shares here. A positive PDUFA decision on a dry eye disease drug later this month could provide a much needed lift to share price and set a BXLT takeover back on track
@n a recent research report, Merrill Lynch sees an upside for investors regarding Shire’s recent share price decline. The price fall has rendered Shire stock as a “tempting” equity investment since it is now valued 15x its 2017 forecast earnings and 20% below the bank’s discounted cash flow target price of 6,000p. Merrill reiterated its Neutral rating on Shire stock, and identified “too many uncertainties” as well. The new terms of a potential Baxalta deal continue to present a risk, since if the bid is raised considerably it might not be accretive enough... Shire’s dry eye disease drug, Lifitegrast, was granted a priority review status in April this year, with a Food and Drug Administration decision date set for October 25. Merrill analysts see uncertainty over Lifitegrast’s review process, along with a “balance risk reward.”
Well there it is. SHPG is going to have to fight this one out.
@Kyle Bass may have to stop calling the U.S. Patent and Trademark Office a “kangaroo court.” The agency’s Patent Trial and Appeal Board agreed Wednesday to review a patent for a Shire Plc colitis drug, saying a group set up by Bass’s Hayman Capital hedge fund had a “reasonable likelihood” of proving the patent owned by Cosmo Pharmaceuticals SA is invalid. Shire called the decision to begin the review on Lialda drug patents disappointing but only an initial step of a process that will take about a year. “Shire has a strong track record in protecting its patents,” said Gwen Fisher, a spokeswoman for the company. “This patent in particular has already been upheld despite a previous attack on its validity.”
Agree that MHVWF would be a suitable partner as well. I wonder if BBD has approached any of these other companies, instead of their biggest direct competitors in commercial jets? If not, why not?